NCT03692143Active, not recruiting
Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP
Effect and Cost Comparation of Different Treatment Strategies for Osteoporotic Vertebral Fractures (OVF): Teriparatide Injection and Percutaneous Vertebroplasty (PVP)
Source: ClinicalTrials.gov · Last updated 2 Oct 2018
Brief summary (registry, in English)
This study aimed to compare teriparatide treatments and PVPs, focusing on its effects on life qualities and effect/coast ratio and evaluate which method is better for patients.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 19 Sept 2018
- Start date
- 1 Jan 2017
- Primary completion date
- 1 Mar 2025
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Diseases
- Osteoporosis
- NCT number
- NCT03692143
What you commit to
- Study type: Observational
- Planned participants: 90
- From 1 Jan 2017 to the primary completion date, 1 Mar 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Serious other illness or disease which effecting quality of life occurs later in treatment
Other
- unwilling to anticipate the trial
Who the study is looking for
- 1.postmenopausal women with osteoporotic fractures 2.treated with teriparatide 3.or treated with vertebroplasty 4.or treated with teriparatide after vertebroplasty 5.or treated with Fosamax 6. willing to anticipate the trial
Age in the registry: 49 years to 99 years · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.